Biovail Dodges Antitrust Class Actions Over Tiazac
An appeals court has rejected four antitrust class actions by wholesale drug purchasers claiming that Biovail Inc. violated antitrust laws by using patent litigation to keep Andrx Pharmaceuticals Inc. from making...To view the full article, register now.
Already a subscriber? Click here to view full article